Global Acute Myeloid Leukemia (AML) Therapeutics Market Projected to Reach $1.6 Billion by 2030
The “Acute Myeloid Leukemia (AML) Therapeutics – Global Strategic Business Report” by ResearchAndMarkets.com reveals a robust growth projection for the AML therapeutics market.
Estimated at US$587.6 Million in 2022, it is anticipated to reach US$1.6 Billion by 2030, exhibiting a CAGR of 13.4% during 2022-2030. Cytarabine and Anthracycline Drugs segments are key contributors to this growth.
Key Market Insights:
1. Segment Analysis:
• Cytarabine segment projected to record a notable CAGR of 15.6%, reaching US$571.6 Million by 2030.
• Anthracycline Drugs segment estimated to grow at a CAGR of 14.5% over the next 8 years.
2. Regional Trends:
• The U.S. AML Therapeutics market estimated at US$217.3 Million in 2022.
• China expected to reach US$151 Million by 2030, trailing a CAGR of 15.4% from 2022 to 2030.
3. Market Drivers:
• High incidence and prevalence of AML driving market growth.
• Growing elderly population, especially those aged 65+, considered a vital growth driver.
• Advances in pharmacology and molecular biology promoting AML drug development.
4. Market Trends & Drivers:
• Rising investments in AML Therapeutics R&D.
• Evolving models of care, including virtual/telemedicine consultations.
• Impact of COVID-19 on cancer patients and AML therapeutics.
5. Competitive Landscape:
• Competitive market presence analysis, key competitor market shares, and global competitiveness insights included.
• Features special discussions on the global economic climate and market sentiment.
Market Overview
The report provides comprehensive insights into the AML therapeutics market, covering recent launches, global market outlook, treatment targets, and existing & potential therapeutic targets. It discusses the impact of COVID-19 on cancer patients and AML therapeutics, emphasizing the evolving models of care and the competitive landscape.
The projected growth of the AML therapeutics market, fueled by advancements in pharmacology and molecular biology, underscores the importance of ongoing research and development in this critical healthcare segment. The report offers a detailed analysis of market trends, drivers, and competitive dynamics, providing stakeholders with valuable information to navigate the evolving landscape.
